SCHEMBL3596936

SCHEMBL3596936

O=[N+]([O-])c1ccc2c(C(O)(CNc3nccs3)C(F)(F)F)cn(Cc3ccccc3)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.41
ALDH1A1 P00352 4/20 0.41
RAB9A P51151 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MAPT P10636 3/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
LMNA P02545 2/20 0.35
MAPK1 P28482 2/20 0.35
HTT P42858 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
NR1I2 O75469 1/20 0.35
SCN3A Q9NY46 1/20 0.35
KAT2B Q92831 1/20 0.35
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
KDM4E B2RXH2 1/20 0.35
CNR1 P21554 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3603046 0.88 ALDH1A1 (0.38) ALDH1A1SMN1; SMN2MAPTMEN1KMT2A
SCHEMBL3598154 0.86 KMT2A (0.38) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT
SCHEMBL3603757 0.85 ALDH1A1 (0.38) ALDH1A1NPSR1SMN1; SMN2MAPTMEN1
SCHEMBL3594391 0.85 KMT2A (0.44) NPC1ALDH1A1RAB9ANPSR1SMN1; SMN2
SCHEMBL3593102 0.85 PDE4A (0.38) ALDH1A1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL3596002 0.83 HTR2C (0.44) ALDH1A1NPSR1SMN1; SMN2MAPTMEN1
SCHEMBL3603384 0.82 L3MBTL1 (0.42) ALDH1A1NPSR1SMN1; SMN2MAPTMEN1
SCHEMBL3595743 0.82 KMT2A (0.38) ALDH1A1RAB9ANPSR1SMN1; SMN2MAPT
SCHEMBL3591565 0.82 PDE4A (0.37) ALDH1A1RAB9ASMN1; SMN2MAPTMEN1
SCHEMBL3591550 0.81 MAPT (0.42) NPC1ALDH1A1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-07-29 US disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed
EP-1930320-A1 NOVEL FUSED PYRROLE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190768-A1 NOVEL FUSED PYROLE DERIVATIVE NR3C1, NR3C2, NR0B1 NPC1 4800/4885ALDH1A1 4118/4885RAB9A 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.